Name PID No. SID No. Age / Sex Type Ref. Dr	: Mrs. SMT UMAIYAL S : MED111517899 : 223003082 : 50 Year(s) / Female : OP : MediWheel	Collection On : 2 Report On : 2	5/02/2023 8:12 AM 25/02/2023 8:54 AM 27/02/2023 5:58 PM 01/03/2023 1:38 PM	DIAGNOSTICS
<u>Investiga</u>	Investigation		<u>Unit</u>	<u>Biological</u> Reference Interval
TYPINC (EDTA BI INTERPI	BLOOD GROUPING AND Rh TYPING (EDTA Blood/Agglutination) INTERPRETATION: Reconfirm the Blood gro Complete Blood Count With - ESR		e blood transfusion	
Haemog (EDTA Bl	lobin ood/Spectrophotometry)	12.6	g/dL	12.5 - 16.0
Packed C	Cell Volume(PCV)/Haematocrit	38.3	%	37 - 47
RBC Co		4.23	mill/cu.mm	4.2 - 5.4
	orpuscular Volume(MCV) ood/Derived from Impedance)	90.6	fL	78 - 100
	orpuscular Haemoglobin(MCH) ood/Derived from Impedance)	29.8	pg	27 - 32
concentr	orpuscular Haemoglobin ration(MCHC) ood/Derived from Impedance)	32.9	g/dL	32 - 36
RDW-C		12.7	%	11.5 - 16.0
RDW-SI (EDTA BI	D ood/Derived from Impedance)	40.27	fL	39 - 46
	ukocyte Count (TC) ood/Impedance Variation)	7890	cells/cu.mm	4000 - 11000
Neutropl (EDTA Bl <i>Cytometry</i>	ood/Impedance Variation & Flow	57.5	%	40 - 75
Lympho (EDTA Bl <i>Cytometry</i>	ood/Impedance Variation & Flow	32.9	%	20 - 45
Eosinopl (EDTA Bl Cytometry	ood/Impedance Variation & Flow	1.9	%	01 - 06
	Gurupriya J			Dr Gurupriya J







APPROVED BY

The results pertain to sample tested.

Page 1 of 7

Name	: Mrs. SMT UMAIYAL S	
PID No.	: MED111517899	Register On : 25/02/2023 8:12 AM
SID No.	: 223003082	Collection On : 25/02/2023 8:54 AM
Age / Sex	: 50 Year(s) / Female	Report On : 27/02/2023 5:58 PM
Туре	: OP	Printed On : 01/03/2023 1:38 PM

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	7.3	%	01 - 10
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	0.4	%	00 - 02
INTERPRETATION: Tests done on Automated	l Five Part cell count	ter. All abnormal results a	are reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	4.54	10^3 / µl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.60	10^3 / µl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.15	10^3 / µl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.58	10^3 / µl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.03	10^3 / µl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	367	10^3 / µl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	8.3	fL	8.0 - 13.3
PCT (EDTA Blood/Automated Blood cell Counter)	0.30	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Blood/Automated - Westergren method)	41	mm/hr	< 20
BUN / Creatinine Ratio	12.4		6.0 - 22.0
Glucose Fasting (FBS)	106.2	mg/dL	Normal: < 100

(Plasma - F/GOD-PAP)

Ref. Dr

: MediWheel





Dr Gurupriya J Pathologist Reg No: 13-48036

Pre Diabetic: 100 - 125 Diabetic: >= 126

APPROVED BY

The results pertain to sample tested.

Page 2 of 7

Name : Mrs. SMT UMAIYAL S			
PID No. : MED111517899	Register On : 2	5/02/2023 8:12 AM	
SID No. : 223003082	Collection On : 2	25/02/2023 8:54 AM	
Age / Sex : 50 Year(s) / Female	Report On : 2	27/02/2023 5:58 PM	medall
Type : OP	Printed On : (01/03/2023 1:38 PM	DIAGNOSTICS
Ref. Dr : MediWheel			
Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
INTERPRETATION: Factors such as type, qublood glucose level.	uantity and time of foo	d intake, Physical activity	, Psychological stress, and drugs can influence
Glucose, Fasting (Urine) (Urine - F/GOD - POD)	Negative		Negative
Glucose Postprandial (PPBS) (Plasma - PP/GOD-PAP)	128.0	mg/dL	70 - 140
INTERPRETATION: Factors such as type, quantity and time of food Fasting blood glucose level may be higher than resistance, Exercise or Stress, Dawn Phenomer	Postprandial glucose,	because of physiological	surge in Postprandial Insulin secretion, Insulin
Urine Glucose(PP-2 hours) (Urine - PP)	Negative		Negative
Blood Urea Nitrogen (BUN) (Serum/Urease UV/derived)	8.6	mg/dL	7.0 - 21
Creatinine (Serum/ <i>Modified Jaffe</i>)	0.69	mg/dL	0.6 - 1.1
INTERPRETATION: Elevated Creatinine val ingestion of cooked meat, consuming Protein/ such as cefoxitin, cefazolin, ACE inhibitors, an etc.	Creatine supplements, I	Diabetic Ketoacidosis, pro	olonged fasting, renal dysfunction and drugs
Uric Acid (Serum/ <i>Enzymatic</i>)	5.8	mg/dL	2.6 - 6.0
Liver Function Test			
Bilirubin(Total) (Serum/DCA with ATCS)	0.53	mg/dL	0.1 - 1.2
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.13	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.40	mg/dL	0.1 - 1.0
SGOT/AST (Aspartate Aminotransferase) (Serum/ <i>Modified IFCC</i>)	15.4	U/L	5 - 40
SGPT/ALT (Alanine Aminotransferase) (Serum/ <i>Modified IFCC</i>)	21.2	U/L	5 - 41
Dr Gurupriya J Pathologist Reg No: 13-48036 VERIFIED BY	■ 茶		Dr Gurupriya J Pathologist Reg No: 13-48036
			APPROVED BY
The results pertain to sample tested.		Pag	e 3 of 7

Name	: Mrs. SMT UMAIYAL S			
PID No.	: MED111517899	Register On :	25/02/2023 8:12 AM	
SID No.	: 223003082	Collection On :	25/02/2023 8:54 AM	\mathbf{O}
Age / Sex	: 50 Year(s) / Female	Report On :	27/02/2023 5:58 PM	medall
Туре	: OP	Printed On :	01/03/2023 1:38 PM	DIAGNOSTICS

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	27.3	U/L	< 38
Alkaline Phosphatase (SAP) (Serum/ <i>Modified IFCC</i>)	77.5	U/L	42 - 98
Total Protein (Serum/ <i>Biuret</i>)	6.74	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.06	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	2.68	gm/dL	2.3 - 3.6
A : G RATIO (Serum/ <i>Derived</i>)	1.51		1.1 - 2.2
<u>Lipid Profile</u>			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	297.2	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	219.7	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >=500

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the `usual_circulating level of triglycerides during most part of the day.

HDL Cholesterol (Serum/Immunoinhibition)	54.3	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 50 - 59 High Risk: < 50
Dr Gurupriya J Pathologist Reg No: 13-48036 VERIFIED BY			Dr Gurupriya J Pathologist Reg No: 13-48036 APPROVED BY

The results pertain to sample tested.

Ref. Dr

: MediWheel

Page 4 of 7

Name	: Mrs. SMT UMAIYAL S		
PID No.	: MED111517899	Register On : 25/02/2023 8:12 AM	
SID No.	: 223003082	Collection On : 25/02/2023 8:54 AM	\mathbf{O}
Age / Sex	: 50 Year(s) / Female	Report On : 27/02/2023 5:58 PM	medall
Туре	: OP	Printed On : 01/03/2023 1:38 PM	DIAGNOSTICS

Ref. Dr : MediWheel

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
LDL Cholesterol (Serum/Calculated)	199	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	43.9	mg/dL	< 30
Non HDL Cholesterol (Serum/Calculated)	242.9	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >=220

INTERPRETATION: 1.Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

Total Cholesterol/HDL Cholesterol Ratio (Serum/ <i>Calculated</i>)	5.5		Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/ <i>Calculated</i>)	4		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	3.7		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
<u>Glycosylated Haemoglobin (HbA1c)</u>			
HbA1C (Whole Blood/ <i>HPLC</i>)	5.7	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5


INTERPRETATION: If Diabetes - Good control : 6.1 - 7.0 %, Fair control : 7.1 - 8.0 %, Poor control >= 8.1 %



The results pertain to sample tested.

Page 5 of 7

Name	: Mrs. SMT UMAIYAL S			
PID No.	: MED111517899	Register On : 2	5/02/2023 8:12 AM	
SID No.	: 223003082	Collection On : 2	25/02/2023 8:54 AM	\mathbf{O}
Age / Sex	: 50 Year(s) / Female	Report On : 2	27/02/2023 5:58 PM	medall
Туре	: OP	Printed On : 0	01/03/2023 1:38 PM	DIAGNOSTICS
Ref. Dr	: MediWheel			
Investigation		<u>Observed</u> <u>Value</u>	Unit	<u>Biological</u> Reference Interval
Estimate (Whole Blo	d Average Glucose	116.89	mg/dL	
 INTERPRETATION: Comments HbA1c provides an index of Average Blood Glucose levels over the past8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations. Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency, hypertriglyceridemia,hyperbilirubinemia,Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbA1C values. Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly,Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c. THYROID PROFILE / TFT_ 				
	odothyronine) - Total emiluminescent Immunometric Assay	1.00	ng/ml	0.7 - 2.04
Comment	ariation can be seen in other conditio	n like pregnancy, drug	s, nephrosis etc. In such	n cases, Free T3 is recommended as it is
	xine) - Total emiluminescent Immunometric Assay	6.76	μg/dl	4.2 - 12.0
Comment	ariation can be seen in other condition	n like pregnancy, drug	s, nephrosis etc. In such	n cases, Free T4 is recommended as it is
	yroid Stimulating Hormone) emiluminescent Immunometric Assay	2.86	µIU/mL	0.35 - 5.50
 INTERPRETATION: Reference range for cord blood - upto 20 1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0 (Indian Thyroid Society Guidelines) Comment: 1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI. 2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations. 3.Values&amplt0.03 μIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals. 				
	Gurupriya J			Dr Gurupriya J



APPROVED BY

The results pertain to sample tested.

Pathologist Reg No: 13-48036

VERIFIED BY

Page 6 of 7

Name	: Mrs. SMT UMAIYAL S
PID No.	: MED111517899
SID No.	: 223003082
Age / Sex	: 50 Year(s) / Female
Туре	: OP

: MediWheel

Register On	:	25/02/2023 8:12 AM
Collection On	:	25/02/2023 8:54 AM
Report On	:	27/02/2023 5:58 PM
Printed On	:	01/03/2023 1:38 PM



Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> Reference Interval
<u>Urine Analysis - Routine</u>			
COLOUR (Urine)	Yellow		Yellow to Amber
APPEARANCE (Urine)	Clear		Clear
Protein (Urine/Protein error of indicator)	Negative		Negative
Glucose (Urine/GOD - POD)	Negative		Negative
Pus Cells (Urine/Automated ~Flow cytometry)	7 - 8	/hpf	NIL
Epithelial Cells (Urine/Automated ⁻ Flow cytometry)	1 - 2	/hpf	NIL
RBCs (Urine/Automated ⁻ Flow cytometry)	NIL	/hpf	NIL
Casts (Urine/Automated ⁻ Flow cytometry)	NIL	/hpf	NIL
Crystals (Urine/Automated ⁻ Flow cytometry)	NIL	/hpf	NIL
Others	NIL		

(Urine)

Ref. Dr

INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.







APPROVED BY

-- End of Report --

The results pertain to sample tested.

Name	: Mrs. SMT UMAIYAL S	Register On	: 25/02/2023 8:12 AM
PID No.	: MED111517899	Collection On	: 25/02/2023 8:54 AM
SID No.	: 223003082	Report On	: 27/02/2023 5:58 PM
Age / Sex	: 50 Year(s) / Female	Printed On	[:] 01/03/2023 1:38 PM
Ref. Dr	: MediWheel	OP / IP	: OP



PAP Smear by LBC(Liquid based Cytology)

SPECIMEN NO: Cy 480/2023

MICROSCOPIC FINDINGS:

ADEQUACY: Satisfactory.

PREDOMINANT CELLS: Squamous cells.

BACKGROUND: Clean.

ORGANISMS: Fungal organisms, morphologically consistent with Candida species.

IMPRESSION:

Vault smear:

Candidiasis.

Negative for intraepithelial lesion/ malignancy.





APPROVED BY

-- End of Report --

The results pertain to sample tested.

Page 1 of 1



Name	Mrs.SMT UMAIYAL S	ID	MED111517899
Age & Gender	50/FEMALE	Visit Date	25/02/2023
Ref Doctor Name	MediWheel		

MAMMOGRAPHY

REPORT

Cranio-caudal and Medio-lateral oblique views of both breasts were studied.

Both breasts are fatty with fibroglandular densities (ACR Type B parenchyma).

A small round, well circumscribed, high-density lesion, measuring 5.3 x 3.4 mm is noted in the 3 O' clock position of the left breast.

Both breasts show vascular calcification.

No breast asymmetry noted.

No intramammary ductal dilatation identified.

No obvious spiculation or architectural distortion noted.

Both nipples are not retracted.

There is no evidence of focal or diffuse thickening of skin or subcutaneous tissue of both breasts.

The retro-mammary spaces appear normal.

Bilateral axillae are clear.

IMPRESSION:

- ACR Type B parenchyma.
- Left Breast lesion as described above- BIRADS II.
 - Suggested USG/ FNAC Correlation.
 - Suggested Annual Review Scans- ACR guidelines.

4

Dr Sharanya.S MD, DNB Radiologist

REPORT DISCLAIMER

1. This is only a radiologincal imperssion. Like other investigations, radiological investication also have limitation. Therefore radiologincal reports should be interpreted in correlation with clinical and pathological findings.

- 2. The results reported here in are subject to interpretation by qualified medical professionals only.
- 3.Customer identities are accepted provided by the customer or their representative.

7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,

8. If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.

9.Liability is limited to the extend of amount billed.

10.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.

11.Disputes, if any, with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only.

^{4.}information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.

^{5.}If any specimen/sample is received from any others laboratory/hospital, its is presumed that the sample belongs to the patient identified or named.

^{6.}Test results should be interpreted in context of clinical and other findings if any. In case of any clarification /doubt, the refrering doctor/patient can contact the respective section head of the laboratory.



Name	Mrs.SMT UMAIYAL S	ID	MED111517899
Age & Gender	50/FEMALE	Visit Date	25/02/2023
Ref Doctor Name	MediWheel		

Category - (BIRADS classification)

- Category 0: Assessment incomplete. Category 1: Negative (normal).
- Category 2: Benign. Category 3: Probably benign finding.

Category 4: Suspicious abnormality. Category 4a: Low suspicion 4b - Intermediate suspicion.

Category 4c: Moderate suspicion. Category 5: High suggestive of malignancy.

Category 6: Known biopsy proven malignancy.

NOTE: Please bring your old mammogram film for the next visit.

REPORT DISCLAIMER

- 1. This is only a radiologincal imperssion. Like other investigations, radiological investication also have limitation. Therefore radiologincal reports should be interpreted in correlation with clinical and pathological findings.
- 2. The results reported here in are subject to interpretation by qualified medical professionals only.
- 3.Customer identities are accepted provided by the customer or their representative.
- 4.information about the customer's condition at the time of sample collection such as fasting, food consumption, medication, etc are accepted as provided by the customer or representative and shall not be investigated for its truthfulness.
- 5.If any specimen/sample is received from any others laboratory/hospital, its is presumed that the sample belongs to the patient identified or named.
- 6.Test results should be interpreted in context of clinical and other findings if any.In case of any clarification /doubt, the refrering doctor/patient can contact the respective section head of the laboratory.
- 7.Results of the test are influenced by the various factors such as sensitivity, specificity of the procedures of the tests, quality of the samples and drug interactions etc.,
- 8.If the test results are found not to be correlating clinically can contact the lab in charge for clarification or retesting where practicable within 24 hours from the time of issue of results.
- 9.Liability is limited to the extend of amount billed.
- 10.Reports are subject to interpretation in their entirety.partial or selective interpretation may lead to false opinion.
- 11.Disputes, if any, with regard to the report findings are subject to the exclusive jurisdiction of the competent courts chennai only.